BRPI0410745A - inibidores de indazol, benzisoxazol e benzisotiazol quinase - Google Patents

inibidores de indazol, benzisoxazol e benzisotiazol quinase

Info

Publication number
BRPI0410745A
BRPI0410745A BRPI0410745-4A BRPI0410745A BRPI0410745A BR PI0410745 A BRPI0410745 A BR PI0410745A BR PI0410745 A BRPI0410745 A BR PI0410745A BR PI0410745 A BRPI0410745 A BR PI0410745A
Authority
BR
Brazil
Prior art keywords
benzisoxazole
indazole
kinase inhibitors
compounds
benzisothiazole
Prior art date
Application number
BRPI0410745-4A
Other languages
English (en)
Inventor
Yujia Dai
Steven K Davidsen
Anna M Ericsson
Kresna Hartandi
Zhiqin Ji
Michael R Miachelides
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/443,254 external-priority patent/US20040235892A1/en
Priority claimed from US10/842,292 external-priority patent/US7297709B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0410745A publication Critical patent/BRPI0410745A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

"INIBIDORES DE INDAZOL, BENZISOXAZOL E BENZISOTIAZOL QUINASE". Compostos com a fórmula (I) são usados para inibir tirosina quinases da proteína. A presente invenção também descreve métodos de fazer os compostos, composições contendo os compostos e métodos de tratamento usando os compostos.
BRPI0410745-4A 2003-05-22 2004-05-21 inibidores de indazol, benzisoxazol e benzisotiazol quinase BRPI0410745A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/443,254 US20040235892A1 (en) 2003-05-22 2003-05-22 Indazole and benzisoxazole kinase inhibitors
US10/842,292 US7297709B2 (en) 2003-05-22 2004-05-10 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
PCT/US2004/016166 WO2004113304A1 (en) 2003-05-22 2004-05-21 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0410745A true BRPI0410745A (pt) 2006-06-27

Family

ID=33544008

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410745-4A BRPI0410745A (pt) 2003-05-22 2004-05-21 inibidores de indazol, benzisoxazol e benzisotiazol quinase

Country Status (20)

Country Link
EP (2) EP1638941B1 (pt)
JP (2) JP4810427B2 (pt)
KR (1) KR100976076B1 (pt)
CN (2) CN102417487A (pt)
AT (1) ATE469888T1 (pt)
AU (2) AU2004249675B2 (pt)
BR (1) BRPI0410745A (pt)
CA (1) CA2526430C (pt)
CY (1) CY1110742T1 (pt)
DE (1) DE602004027490D1 (pt)
DK (1) DK1638941T3 (pt)
ES (2) ES2346538T3 (pt)
IL (1) IL171976A0 (pt)
MX (1) MXPA05012596A (pt)
NZ (1) NZ543614A (pt)
PL (1) PL1638941T3 (pt)
PT (1) PT1638941E (pt)
SI (1) SI1638941T1 (pt)
TW (1) TWI328579B (pt)
WO (1) WO2004113304A1 (pt)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR046078A1 (es) 2003-08-06 2005-11-23 Senomyx Inc Nuevos sabores, modificadores de sabores, sustancias gustativas, mejoradores de gusto, sustancias gustativas y/o mejoradoras del gusto umani o dulce y uso de los mismos.
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102004028862A1 (de) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
ATE554087T1 (de) 2004-10-29 2012-05-15 Abbott Lab Neue kinaseinhibitoren
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
EP1683796A1 (en) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
US7842809B2 (en) 2005-01-24 2010-11-30 Bayer Schering Pharma Ag Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
ATE525073T1 (de) * 2005-01-28 2011-10-15 Novartis Ag Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
JP4734346B2 (ja) 2005-02-04 2011-07-27 セノミックス インコーポレイテッド 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
EP1959926A1 (en) * 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
ES2385404T3 (es) 2006-04-14 2012-07-24 Abbott Laboratories Procedimiento para la preparación de ureas de indazolilo que inhiben los receptores vaniloides de subtipo 1 (VR1)
ES2640453T3 (es) 2006-04-21 2017-11-03 Senomyx, Inc. Procesos para preparar composiciones saborizantes sólidas
TW200815437A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1867648A1 (en) * 2006-06-13 2007-12-19 Bayer Schering Pharma Aktiengesellschaft Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them.
EP1867647A1 (en) * 2006-06-13 2007-12-19 Bayer Schering Pharma Aktiengesellschaft Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them.
EP1870410A1 (en) * 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
EP1932845A1 (en) * 2006-12-15 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP2125808A2 (en) * 2006-12-15 2009-12-02 Bayer Schering Pharma Aktiengesellschaft 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
ES2457418T3 (es) * 2007-07-16 2014-04-25 Abbvie Inc. Indazoles, bencisoxazoles y bencisotiazoles como inhibidores de proteína cinasas
US7772404B2 (en) * 2007-10-19 2010-08-10 Abbott Laboratories Crystalline form 2 of the chemotherapeutic N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea
US7994208B2 (en) * 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic
US7943782B2 (en) 2007-10-19 2011-05-17 Abbott Laboratories Crystalline chemotherapeutic
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic
US7960564B2 (en) 2007-10-19 2011-06-14 Abbott Laboratories Crystalline chemotherapeutic
KR20100090683A (ko) 2007-11-09 2010-08-16 제넨테크, 인크. 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
JP5913980B2 (ja) 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド 免疫グロブリン変異体及びその用途
AR074199A1 (es) * 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
BRPI0918211A2 (pt) 2008-12-23 2015-12-08 Genentech Inc métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf
AU2010221438C1 (en) * 2009-03-03 2015-01-29 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
US20100227905A1 (en) * 2009-03-03 2010-09-09 Alcon Research, Ltd. Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye
US8912236B2 (en) 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
CN102639537B (zh) * 2009-07-10 2015-07-22 拜耳知识产权有限责任公司 吲唑基取代的二氢异*唑并吡啶及其使用方法
AU2010273585B2 (en) 2009-07-13 2015-04-23 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
MX2012001974A (es) * 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.
WO2011038579A1 (en) * 2009-09-30 2011-04-07 Zhejiang Beta Pharma Inc. Compounds and compositions as protein kinase inhibitors
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
BR112012013093A2 (pt) 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US8987275B2 (en) 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
KR101910779B1 (ko) 2010-11-15 2018-10-22 파이브 프라임 테라퓨틱스, 인크. Ｆｇｆｒ１ 세포밖 도메인 조합치료
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
JP6250533B2 (ja) 2011-04-20 2017-12-20 アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． エンドグリンポリペプチドおよびその使用
US20140107151A1 (en) 2011-05-17 2014-04-17 Principia Biophama Inc. Tyrosine kinase inhibitors
CN102432595B (zh) * 2011-09-14 2013-09-25 湖南有色凯铂生物药业有限公司 N-吲哚-1-酰胺类化合物及作为抗癌药物的应用
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
CN110538322A (zh) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
US20160067307A1 (en) 2013-05-01 2016-03-10 Five Prime Therapeutics, Inc. Methods of treating cancer
SG10201703977UA (en) 2013-05-23 2017-06-29 Five Prime Therapeutics Inc Methods of treating cancer
CA2914815A1 (en) * 2013-06-11 2014-12-18 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof
US8759538B1 (en) 2013-06-13 2014-06-24 Abbvie Inc. Crystalline chemotherapeutic
CN103524421B (zh) * 2013-09-29 2015-04-01 镇江蓝德特药业科技有限公司 新型萘脲类衍生物及其医疗应用
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3851118A1 (en) 2013-10-25 2021-07-21 Acceleron Pharma Inc. Endoglin peptides to treat fibrotic diseases
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
EP2985043A1 (en) 2014-08-14 2016-02-17 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Process for manufacturing a customizable medical device and device obtained by said process
CN106794247B (zh) 2014-09-15 2022-12-02 豪夫迈·罗氏有限公司 抗体配制剂
CN104326985A (zh) * 2014-09-24 2015-02-04 安润医药科技（苏州）有限公司 利你法尼的制备方法
EP3212670B1 (en) 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
EP3230272B1 (en) 2014-12-10 2020-08-19 Kala Pharmaceuticals, Inc. 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
CN104725319A (zh) * 2015-03-11 2015-06-24 西安交通大学 一种具有抗肿瘤活性的1h-吲唑-3-氨基联苯脲类化合物及其制备方法和应用
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016249981B2 (en) 2015-04-13 2022-02-17 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016187220A2 (en) 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
MX2018000948A (es) 2015-07-23 2018-09-27 Inhibrx Inc Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
MX2018006181A (es) 2015-11-23 2018-09-24 Five Prime Therapeutics Inc Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
ES2904615T3 (es) * 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
CN105906568A (zh) * 2016-04-28 2016-08-31 西安交通大学 一种具有抗肿瘤活性的环丙二酰胺化合物及其制备方法和应用
JP2019519536A (ja) 2016-07-01 2019-07-11 ファイブ プライム セラピューティクス， インコーポレイテッド Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法
EP3543228B1 (en) * 2016-11-17 2022-12-28 3D Medicines (Beijing) Co., Ltd. Compound having anticancer activity, and preparation method and application thereof
CN108117551B (zh) * 2016-11-29 2020-03-27 华东理工大学 取代(1H-吡唑[3,4-b]吡啶)脲类化合物及其抗肿瘤用途
CN110709420A (zh) 2017-03-31 2020-01-17 戊瑞治疗有限公司 使用抗gitr抗体的癌症组合疗法
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
AU2018312349A1 (en) 2017-08-01 2020-02-06 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
EP3681535A1 (en) 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
CN112543642A (zh) 2018-08-29 2021-03-23 戊瑞治疗有限公司 CD80胞外结构域Fc融合蛋白给药方案
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
CA3149719A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
EP4054721A1 (en) 2019-11-04 2022-09-14 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
KR20230020379A (ko) 2020-01-06 2023-02-10 하이파이바이오 (에이치케이) 리미티드 항-tnfr2 항체 및 이의 용도
CN120647763A (zh) 2020-01-07 2025-09-16 高诚生物医药公司 抗半乳糖凝集素-9抗体及其用途
US20240228578A1 (en) 2020-02-26 2024-07-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein therapy
CN116724051A (zh) 2020-08-10 2023-09-08 上海寻百会生物技术有限公司 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
CA3198456A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
AU2022316139A1 (en) 2021-07-23 2024-01-18 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof
AU2022379973A1 (en) 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
US20260028407A1 (en) 2022-07-15 2026-01-29 Fibrogen, Inc. Modified anti-galectin-9 antibody and uses thereof
PE20251075A1 (es) 2022-07-22 2025-04-10 Bristol Myers Squibb Co Anticuerpos que se unen a la pad4 humana y usos de los mismos
WO2024040216A2 (en) 2022-08-19 2024-02-22 Fibrogen, Inc. Anti-ccr8 antibodies and uses thereof
CN116535359B (zh) * 2023-05-12 2026-02-24 南昌双天使生物科技开发有限公司 一种含吲唑基的羟肟酸衍生物及其应用
KR20260041867A (ko) 2023-07-21 2026-03-27 브리스톨-마이어스 스큅 컴퍼니 Pad4 조정제의 시트룰린화 및 활성을 평가하는 방법
KR20260049597A (ko) 2023-08-04 2026-04-14 알닐람 파마슈티칼스 인코포레이티드 Ctnnb1-관련 질환을 치료하기 위한 방법 및 조성물
AU2024417420A1 (en) * 2024-01-03 2026-01-29 Iregene Therapeutics., Ltd Biphenyl derivative, pharmaceutical composition and use thereof
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2971842A (en) * 1956-03-21 1961-02-14 Gen Aniline & Film Corp Light sensitive layers for photomechanical reproduction
GB816283A (en) * 1957-06-28 1959-07-08 Corson G & W H Road building
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AU1818400A (en) * 1998-11-12 2000-05-29 Eli Lilly And Company Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
WO2002055517A2 (en) * 2000-12-20 2002-07-18 Jingrong Cui 4-(hetero)aryl substituted indolinones
WO2003051847A1 (en) * 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
WO2003087072A1 (en) * 2002-03-29 2003-10-23 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for endothelial disorder
MXPA04011417A (es) * 2002-05-17 2005-02-14 Pharmacia Italia Spa Derivados de aminoindazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
JP4648703B2 (ja) * 2002-09-05 2011-03-09 アベンティス・ファーマ・ソシエテ・アノニム 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物
BR0316606A (pt) * 2002-12-12 2005-10-11 Aventis Pharma Sa Derivados de aminoindazóis e sua utilização como inibidores de quinases

Also Published As

Publication number Publication date
KR100976076B1 (ko) 2010-08-17
CA2526430A1 (en) 2004-12-29
PT1638941E (pt) 2010-08-24
EP1638941B1 (en) 2010-06-02
NZ543614A (en) 2009-09-25
ES2398074T3 (es) 2013-03-13
HK1149757A1 (en) 2011-10-14
AU2004249675A1 (en) 2004-12-29
ATE469888T1 (de) 2010-06-15
JP5336461B2 (ja) 2013-11-06
AU2004249675B2 (en) 2010-04-15
EP2246333A1 (en) 2010-11-03
TWI328579B (en) 2010-08-11
AU2010202984A1 (en) 2010-08-05
HK1089172A1 (en) 2006-11-24
DK1638941T3 (da) 2010-10-11
CN102417487A (zh) 2012-04-18
CA2526430C (en) 2012-07-10
EP1638941A1 (en) 2006-03-29
PL1638941T3 (pl) 2010-11-30
JP4810427B2 (ja) 2011-11-09
DE602004027490D1 (de) 2010-07-15
SI1638941T1 (sl) 2010-11-30
EP2246333B1 (en) 2012-10-24
JP2011088918A (ja) 2011-05-06
JP2007500226A (ja) 2007-01-11
KR20060023970A (ko) 2006-03-15
CN1826324A (zh) 2006-08-30
ES2346538T3 (es) 2010-10-18
MXPA05012596A (es) 2006-02-22
TW200504015A (en) 2005-02-01
CY1110742T1 (el) 2015-06-10
IL171976A0 (en) 2006-04-10
WO2004113304A1 (en) 2004-12-29
CN1826324B (zh) 2011-12-07

Similar Documents

Publication Publication Date Title
BRPI0410745A (pt) inibidores de indazol, benzisoxazol e benzisotiazol quinase
ATE554087T1 (de) Neue kinaseinhibitoren
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
WO2007079164A3 (en) Protein kinase inhibitors
ATE451363T1 (de) 3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
DK1347971T3 (da) Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
DE60205776T2 (de) Indolinon-derivative als protein-kinasehemmer
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
DE60330895D1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
EA201000093A1 (ru) Производные пиридазинона
ATE425160T1 (de) Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
MXPA06010904A (es) Inhibidores de pirazol cinasa triciclicos.
WO2004072029A3 (en) Pyrazolopyridazines useful as inhibitors of protein kinases
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B25A Requested transfer of rights approved

Owner name: ABBVIE BAHAMAS LTD. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements